Business Wire18h
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
Business Wire4d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Yahoo Finance1mon
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...
Nature5y
78 Differential Role of the Lectin Pathway of Complement Activation in Susceptibility to Neonatal Sepsis
Objective: Newborns are highly susceptible to bacterial sepsis. Mannan-binding lectin (MBL), M-, L- and H-ficolin recognize microorganisms and activate the complement system via MBL-associated ...
Nature22d
Mannose-Binding Lectin and Its Role in Immune Response
A study on COVID-19 patients highlighted the role of MASP-2 in the lectin pathway of complement activation. The researchers developed a sensitive assay to measure MASP-2 levels and found that its ...
dmu.ac.uk9y
Dr Umakhanth Venkatraman Girija
During his doctoral research, Umakhanth investigated the protein-protein interactions leading to the lectin pathway of complement activation, an important component of innate immune system. His ...
Hosted on MSN29d
Narsoplimab shows promise in reducing mortality for TA-TMA patients
Narsoplimab, also known as OMS721, is a monoclonal antibody targeting MASP-2, a key player in the lectin pathway of the complement system. The drug has received breakthrough therapy and orphan ...